新型猪瘟与猪流行性腹泻二联疫苗在小鼠中诱导显著Th2偏向性体液免疫应答
研究构建基于CSFV E2蛋白与PEDV S1刺突蛋白亚单位的E2-S1重组融合蛋白二联疫苗,在小鼠中比较其与单独E2或S1疫苗的免疫效果。E2-S1诱导针对CSFV和PEDV的中和抗体滴度及IgG1/IgG2a比值高于单独疫苗,并诱导高IL-4表达而无IFN-γ表达。结果提示E2与S1抗原兼容性良好,E2-S1可诱导强Th2型细胞介导体液免疫应答。
要点
- E2-S1二联疫苗在小鼠中诱导的CSFV和PEDV中和抗体滴度高于单独E2或S1疫苗。
- E2-S1疫苗诱导的IgG1/IgG2a比值高于单独疫苗,提示Th2偏向性应答。
- E2-S1诱导高IL-4表达而无IFN-γ表达,E2与S1抗原兼容性良好。
核心结论
- E2-S1重组融合蛋白可作为针对CSFV和PEDV的新型候选二联疫苗,为猪病联合疫苗奠定基础。
研究设计与样本
- 构建基于CSFV E2蛋白与PEDV S1刺突蛋白亚单位的E2-S1重组融合蛋白疫苗,在小鼠中与单独E2或S1疫苗比较免疫效果。
主要发现
- E2-S1疫苗在小鼠中诱导的抗CSFV和PEDV中和抗体滴度及IgG1/IgG2a比值高于单独E2或S1疫苗。
- E2-S1疫苗诱导高IL-4表达,但未诱导IFN-γ表达。
- 结果提示E2与S1抗原间兼容性良好,E2-S1可诱导强Th2型细胞介导体液免疫应答。
关键数值与推荐
- E2-S1疫苗诱导的中和抗体滴度及IgG1/IgG2a比值高于单独E2或S1疫苗。
- E2-S1疫苗诱导高IL-4表达而无IFN-γ表达。
临床怎么用
- 为减少中国繁殖猪反复接种CSFV和PEDV疫苗所致免疫应激,E2-S1二联疫苗候选策略值得进一步开发。
- E2-S1的Th2偏向性体液免疫特征可用于指导猪用联合疫苗的抗原配伍设计。
局限性
- 研究仅在小鼠中评价免疫应答,尚未在猪或目标动物中验证。
- 摘要未报告样本量、具体抗体滴度数值、P值及保护效力数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many Chinese breeding pigs are repeatedly vaccinated against classical swine fever virus (CSFV) and porcine epidemic diarrhea virus (PEDV), which cause fatal, highly contagious diseases. To reduce their high frequency vaccination-induced immune stress, we constructed a combined vaccine based on the E2 protein of CSFV and the S1 spike protein subunit of PEDV (named E2-S1). In mice, the E2-S1 vaccine elicited higher neutralizing antibody titers and IgG1/IgG2a ratios against CSFV and PEDV than those induced by individual E2 or S1 vaccines. Moreover, it elicited high IL-4 expression, but no IFN-γ expression. The results suggest that good compatibility exists between E2 and S1 antigens, and the E2-S1 vaccine can elicit a strong Th2-type cell-mediated humoral immune response. The E2-S1 recombinant fusion protein provides a novel vaccine candidate against both CSFV and PEDV, laying the foundation for future combination vaccines against swine diseases.
引用
- Ding Y, Luo L, Luo Y, et al. A novel combined vaccine against classical swine fever and porcine epidemic diarrhea viruses elicits a significant Th2-favored humoral response in mice. Vaccine. 2021. PMID: 34246494. doi:10.1016/j.vaccine.2021.06.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。